Vascular inflammation is a stronger predictor of residual cardiovascular risk than LDL cholesterol level among statin-treated patients. This finding from a large analysis of contemporary trials points to a potential new standard of care for atherosclerosis.
A 14,000-patient trial has shown that LDL cholesterol reduction with the non-statin therapy translates to a lower rate of cardiovascular death, heart attack, stroke or revascularization.
This brief review shares a pragmatic road map for managing atherosclerosis in patients who cannot or will not take a statin. And it looks ahead to new statin alternatives on the horizon.
The veteran cardiologist reflects on the meeting’s biggest developments: the new cholesterol guideline, the VITAL trial of vitamin D, the REDUCE-IT controversy and a strikingly potent therapy for lowering Lp(a).
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic researchers have demonstrated for the first time that lowering blood cholesterol levels could enhance the success of a specific type of T-cell immunotherapy in fighting cancer.
A Cleveland Clinic study reveals a mechanism that rapidly destroys high-density lipoprotein (HDL) in people with Type 2 diabetes, negating cardiovascular protections.
This infographic, derived from an editorial by Dr. Steven Nissen, outlines the causes, effects and high stakes of widespread misinformation about statins and cholesterol.
A patient’s healthy diet is fundamental to the success of pain management therapies. Here’s how sugar, processed carbohydrates, damaged fats and oils, and toxins can exacerbate chronic pain.
From heart benefits of diabetes drugs to leadless pacing to expanding populations for TAVR, 2016 was a dynamic year in cardiovascular care. Cleveland Clinic experts reflect on a dozen key developments.
FDA’s late-July approval of the first PCSK9 inhibitor is “a major event in cardiovascular medicine,” says Dr. Steve Nissen. Here’s his expert take on the place of this new cholesterol-lowering class in today’s practice.